Bionik Laboratories Corp. Featured in Fortune and The Verge for Integration of Amazon Echo into ARKE™ Exoskeletons
Company's integration of Echo and Alexa technologies into its exoskeleton featured as innovative first in the market; multiple top media outlets highlight the benefits of the Company's assistive technology solutions to those with mobility issues
TORONTO and BOSTON, Aug. 23, 2017 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB:BNKL) ("Bionik" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported that it has been featured in numerous high profile media publications – including Fortune and The Verge – following the Company's announcement of its integration of Amazon Echo into its ARKE™ lower body exoskeletons earlier this month.
The Company's announcement that its lower body exoskeletons will now utilize Amazon's Echo ("Echo") technology and Alexa Voice Service ("Alexa") drew interest from prominent business and technology publications as a first-to-market innovation.
The article in Fortune features Bionik's ARKE lower body exoskeleton as a technology that could help injured people be more mobile within their own homes, enabling people with spinal cord or other injuries to walk and perform other physical functions they might not otherwise be able to. It also highlights the success of Bionik's assistive robotics for stroke rehabilitation within the clinical setting.
Bionik was also featured in an article by The Verge, which highlights the innovation behind the Company's technology and the integration of Echo and Alexa into its ARKE lower body exoskeletons. The piece discusses how ARKE can be controlled via an app on a tablet or by reacting automatically to users' movements through sensors that detect when the wearer shifts their weight. Now with Echo and Alexa, the ARKE has an enhanced level of control for the user.
"It is a terrific achievement for our company to be featured in premier publications such as Fortune and The Verge, as well as a timely one, as the medical robotics market has begun to garner more attention worldwide," said Peter Bloch, Chief Executive Officer and Chairman of the Board of Bionik Laboratories. "We see great potential for our technology to help alleviate mobility issues for people around the world, and this exposure will help educate the market about our capabilities. We are excited for all of the opportunities ahead of us, and look forward to seeing the difference our technology can make."
The ARKE™ exoskeleton utilizes Bionik's proprietary transmission and actuation system, making it one of the most powerful robotic devices compared to similar systems. It will now include device control, utilizing multiple sensors located throughout the device in combination with Alexa. Users will be able to activate different activity modes, such as Standing and Walking, by saying "Alexa, I'm ready to stand" or "Alexa, I'm ready to walk."
About Bionik Laboratories
Bionik Laboratories (OTCQB:BNKL) is a robotics company focused on providing rehabilitation and mobility solutions to individuals with neurological and mobility challenges from hospital to home. The Company has a portfolio of products focused on upper and lower extremity rehabilitation for stroke and other mobility-impaired patients, including three products on the market and four products in varying stages of development. The InMotion Systems — the InMotion ARM™, InMotion Wrist™, InMotion Hand™ and InMotion AnkleBot™ — are designed to provide intelligent, patient-adaptive therapy in a manner that has been clinically verified to maximize neuro-recovery. Bionik is also developing a lower-body exoskeleton, ARKE™, designed to allow paraplegics as well as other wheelchair users the ability to rehabilitate through walking. ARKE is designed to continually adapt to a patient's ability and provide real-time feedback to the physiotherapist.
For more information, please visit www.bioniklabs.com and connect with us on Twitter, LinkedIn, and Facebook. If you're a shareholder and wish to receive email alerts for Company news, please sign up here.
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for future operations, including plans or objectives relating to the design, development and commercialization of human exoskeletons and other robotic rehabilitation products, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the market and projected market for our existing and planned products and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances, and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions, and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of our products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, volatility in the price of the Company's raw materials, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company does not undertake to update these forward-looking statements.
SOURCE Bionik Laboratories Corp.
Released August 23, 2017